Dr. Steven Nissen to Chair Steering Committee for Landmark ApoA-I Trial
TSX Exchange Symbol: RVX
CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the formation of the Steering Committee for the RVX-208 Phase 2b clinical trial assessing atherosclerosis by IVUS (Intravascular Ultrasound). This is a study in Acute Coronary Syndrome patients expected to start in 2009.
"We are honored to have an experienced and highly esteemed group of
internationally recognized cardiologists to lead this important IVUS
atherosclerosis study," said Mr. Donald J. McCaffrey, President and CEO of
Resverlogix. "ApoA-IMilano infusions have previously been shown to be the
most efficient means to reduce atherosclerosis, we will now test the
hypothesis that a permanent endogenous ApoA-I increase by oral
administration of RVX-208 has the same capacity".
Appointed members of the Phase 2b IVUS Steering Committee include:
Chairman: Dr. Steven Nissen, M.D., Chairman of the Department of
Cardiovascular Medicine located on the main campus of Cleveland
Principal Investigator: Dr. Stephen Nicholls, M.B.B.S, Ph.D., Medical
Director of Intravascular Ultrasound and Angiography Core
Laboratories at Cleveland Clinic and Clinical Director of the
Cleveland Clinic Center for Cardiovascular Diagnostics and
Dr. Christie M. Ballantyne, M.D., Associate Chief and Professor,
Section of Atherosclerosis and Lipoprotein Research, Baylor College
of Medicine, Houston, Texas.
Dr. John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and
Chairman of the Department of Vascular Medicine at the Academic
Medical Centre (AMC) of the University of Amsterdam, where he holds
the Strategic Chair of Genetics of Cardiovascular Disease and
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved